A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease

NCT01516541 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2220

Enrollment

INDUSTRY

Sponsor class

Conditions

Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD)

Interventions

OTHER: Background care
DRUG: Placebo
DRUG: dalcetrapib

Sponsor

Hoffmann-La Roche